Scott B. Ullem - Oct 31, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Chief Financial Officer
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Oct 31, 2023
Transactions value $
-$187,947
Form type
4
Date filed
10/31/2023, 05:22 PM
Previous filing
Sep 29, 2023
Next filing
Nov 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $267K +7.26K +37.69% $36.75 26.5K Oct 31, 2023 Direct F1
transaction EW Common Stock Sale -$455K -7.26K -27.37% $62.66 19.2K Oct 31, 2023 Direct F1, F2
holding EW Common Stock 266K Oct 31, 2023 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -7.26K -14.29% $0.00 43.5K Oct 31, 2023 Common Stock 7.26K $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $62.40 to $63.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.